 "Cadila hits 52-week low on 14 observations from USFDA for Moraiya plant")
Cadila Healthcare shares hit a 52-week low of Rs 292, down 4 per cent in early morning trade on Monday, extending its Friday’s 3.5 per cent fall on the BSE, after getting 14 observations from US health regulator for its Moraiya plant.
The US Food and Drug Administration (USFDA) have issued 14 observations after inspecting its manufacturing facility at Moraiya in Ahmedabad, Cadila Healthcare said in a regulatory filing.
The USFDA inspected the plant from April 22, 2019 to May 3, 2019. The inspection concluded with 14 observations. There were no repeat observations or data integrity related observations, the drug firm said.
At 09:29 am, the stock was trading 0.38 per cent lower at Rs 303, as compared to 0.89 per cent decline in the S&P BSE Sensex. A combined 849,947 shares have changed hands on the counter on the BSE and NSE so far.
The US Food and Drug Administration (USFDA) have issued 14 observations after inspecting its manufacturing facility at Moraiya in Ahmedabad, Cadila Healthcare said in a regulatory filing.
The USFDA inspected the plant from April 22, 2019 to May 3, 2019. The inspection concluded with 14 observations. There were no repeat observations or data integrity related observations, the drug firm said.
At 09:29 am, the stock was trading 0.38 per cent lower at Rs 303, as compared to 0.89 per cent decline in the S&P BSE Sensex. A combined 849,947 shares have changed hands on the counter on the BSE and NSE so far.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%